Zurich, October 07, 2015. Molecular Partners AG (MOLN) announced today that it has been honored with the EUROPEAN BIOTECHNICA AWARD 2015. The award honors one company that has established a truly disruptive, pioneering technology in biotech or life sciences.
“We are very pleased that the renowned Biotechnica jury recognizes the potential of Molecular Partners’ DARPins,” said Christian Zahnd, Chief Executive Officer of Molecular Partners. “It makes us proud to be recognized for our endeavors to use our DARPin technology to generate products with the potential to significantly benefit patient’s lives.”
The Biotechnica Award 2015 recognized Molecular Partners’ DARPin drug discovery platform and the advancements the company has made toward bringing novel therapeutic options to patients. In June 2015, Molecular Partners’ development partner Allergan initiated two phase III registration trials of the company’s lead molecule, abicipar, for the treatment of wet age-related macular degeneration. Molecular Partners also plans to present clinical interim data by the end of the year from a phase I study of MP0250, a multi-DARPin anti-cancer therapeutic that inhibits both VEGF and HGF from binding to their receptors, thereby blocking tumor growth and tumor spreading.
The award ceremony took place on October 6, during the BIOTECHNICA / LABVOLUTION reception event on the first day of the respective trade fair in Hannover, Germany. A selection of impressive companies from the United States, France, Switzerland and Germany competed for the award. An independent international jury of renowned experts chaired by Dr. Karsten Henco, CEO of HS Life Sciences GmbH in Dusseldorf, selected Molecular Partners AG as the winner.
“We would like to thank the entire Molecular Partners team for their dedication to advancing forward a pipeline of treatments for patients with severe diseases,” said Patrick Amstutz, Chief Operating Officer of Molecular Partners. “The team’s collaborative efforts empower the successful growth and development of our company.”
Additional information on the EUROPEAN BIOTECHNICA AWARD 2015 as well as the BIOTECHNICA and LABVOLUTION 2015 trade shows can be found online at: www.biotechnica.de
About Molecular Partners AG
Molecular Partners is a public, clinical stage, biopharmaceutical company listed on the SIX Swiss Exchange (ticker symbol: MOLN) that is developing a new powerful class of therapies known as DARPins. DARPins are potent, specific and versatile small protein therapies which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to enable a multi-specific approach to treatment which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.
Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. Its most advanced product candidate is abicipar. The company has ongoing research and development partnerships with leading pharmaceutical companies including Allergan and Janssen and is backed by established biotech investors. For more information regarding Molecular Partners, go to: www.molecularpartners.com.
For further details please contact:
Dr. Christian Zahnd, CEO
Dr. Patrick Amstutz, COO
Tel: +41 (0) 44 755 77 00
Tel: +41 (0) 43 344 42 42
Tel: +44 (0) 208 877 8400
This announcement is not an offer to sell, or a solicitation of an offer to purchase, any securities of Molecular Partners AG (the “Company”), nor shall it or any part of it form the basis of, or be relied on in connection with any contract or investment decision. This announcement is not for publication or distribution (directly or indirectly) in or to the United States, Canada, Australia, Japan or any other jurisdiction in which such distribution would be unlawful.
This announcement contains statements that are, or may be deemed to be, forward-looking statements. In some case, these forward-looking statements can be identified by the use of forward-looking terminology or subjective assessments, including the words “potential”, “expects”, “targets”, “designed”, “intends” or “plans” or comparable terminology or by discussions of plans, objectives, targets, goals, future events or in‐ tentions. These forward-looking statements include matters that are not historical facts or which may not otherwise be provable by reference to past events, and are based on assumptions. By their nature, forwardlooking statements are subject to known and unknown risks and uncertainties because they relate to events and/or depend on circumstances that may or may not occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of the Company cannot be relied on as a guide to future performance.
The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. Neither the Company nor any other person undertakes any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement.